Amorphous solid dispersion studies of camptothecin-cyclodextrin inclusion complexes in PEG 6000.

Abstract: The present work focused on the solubility enhancement of the poorly water-soluble anti-cancer agent camptothecin which, in its natural state, presents poor solubility inducing lack of activity with a marked toxicity. A new approach is adopted by using a ternary system including camptothecin (CPT) and cyclodextrins (CDs) dispersed in polyethylene glycol (PEG) 6000. Camptothecin solubility variations in the presence of α-CD, β-CD, γ-CD, hydroxypropyl-α-CD (HPα-CD), hydroxypropyl-β-CD (HPβ-CD), permethyl-β-CD (PMβ-CD) and sulfobutyl ether-β-CD (SBEβ-CD), were evaluated by Higuchi solubility experiments. In the second part, the most efficient camptothecin/P-CDs binary systems, mainly HPβ-CD and PMβ-CD, were dispersed in PEG 6000. In addition to a drug release and modeling evaluation, the CPT interactions with CDs and PEG 6000 to prepared the amorphous solid dispersion in the binary and ternary systems were investigated by Fourier transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), thermogravimetric analyses (TGA) and X-ray powder diffraction (XRPD). The results showed that HPβ-CD and PMβ-CD were the most efficient for camptothecin solubilization with highest apparent equilibrium constants. Dissolution studies showed that percentage of CPT alone after two hour in 0.1 M HCI medium, did not exceed 16%, whereas under the same conditions, CPT/PMβ-CD complex reached 76%. When dispersing the binary systems CPT/β-CDs in PEG 6000, the velocity and the percentage of CPT release were considerably improved whatever the CD used, reaching the same value of 85%. The binary and ternary systems characterization demonstrated that CPT inclused into the CDs cavity, replacing the water molecules. Furthermore, a drug transition from crystalline to amorphous form was obtained when solid dispersion is realized. The present work demonstrated that ternary complexes are promising systems for CPT encapsulation, and offer opportunities to use non toxic and commonly solubilizing carriers: βCD and PEG 6000 to improve bioavailability.